18.62
전일 마감가:
$18.00
열려 있는:
$18.01
하루 거래량:
1.18M
Relative Volume:
0.74
시가총액:
$1.06B
수익:
$322.02M
순이익/손실:
$-102.47M
주가수익비율:
-10.18
EPS:
-1.8295
순현금흐름:
$-80.57M
1주 성능:
+11.56%
1개월 성능:
-17.54%
6개월 성능:
-35.70%
1년 성능:
-61.62%
Procept Biorobotics Corp Stock (PRCT) Company Profile
명칭
Procept Biorobotics Corp
전화
(650) 232-9832
주소
150 BAYTECH DRIVE, SAN JOSE
Compare PRCT vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
PRCT
Procept Biorobotics Corp
|
18.62 | 1.01B | 322.02M | -102.47M | -80.57M | -1.8295 |
|
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Procept Biorobotics Corp Stock (PRCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-06 | 개시 | Robert W. Baird | Neutral |
| 2026-02-26 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2026-02-26 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-12-12 | 개시 | UBS | Buy |
| 2025-12-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-09-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-07-09 | 개시 | Stephens | Overweight |
| 2025-07-07 | 개시 | Oppenheimer | Perform |
| 2024-12-02 | 개시 | Morgan Stanley | Overweight |
| 2024-11-14 | 개시 | Jefferies | Hold |
| 2023-08-11 | 개시 | Piper Sandler | Overweight |
| 2023-05-31 | 개시 | William Blair | Outperform |
| 2022-10-31 | 개시 | BTIG Research | Neutral |
| 2022-10-25 | 개시 | Truist | Buy |
| 2022-09-02 | 개시 | Wells Fargo | Overweight |
| 2022-07-15 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-06-23 | 개시 | B. Riley Securities | Buy |
| 2021-10-11 | 개시 | BofA Securities | Buy |
| 2021-10-11 | 개시 | Cowen | Outperform |
| 2021-10-11 | 개시 | Goldman | Neutral |
| 2021-10-11 | 개시 | Guggenheim | Buy |
| 2021-10-11 | 개시 | SVB Leerink | Outperform |
모두보기
Procept Biorobotics Corp 주식(PRCT)의 최신 뉴스
UBS Downgrades PROCEPT BioRobotics to Neutral From Buy, Cuts Price Target to $20 From $30 - marketscreener.com
PROCEPT BIOROBOTICS CORPORATION (PRCT) INVESTOR ALERT Investors With Large Losses in PROCEPT BioRobotics Corporation Should Contact Bernstein Liebhard LLP To Discuss Their Rights - Supply Chain Digital
PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit - AOL.ca
PROCEPT BioRobotics Corporation Revenue Breakdown – BOATS:PRCT - TradingView
INVESTOR ALERT: Securities Class Action Filed Against PROCEPT BioRobotics Corporation – Investors Encouraged to Contact Kirby McInerney LLP - Business Wire
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - marketscreener.com
Law Offices of Howard G. Smith Encourages PROCEPT BioRobotics Corporation (PRCT) Shareholders To Inquire About Securities Fraud Class Action - WBOC TV
Rosen Law Firm Urges PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
Notice to Long-Term Shareholders of Cogent Communications - GlobeNewswire
Notice to Long-Term Shareholders of Cogent Communications Holdings, Inc. (NASDAQ: CCOI); EquipmentShare.com, Inc. (NASDAQ: EQPT); Photronics, Inc. (NASDAQ: PLAB); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Class action lawsuit filed against PROCEPT BioR... - Pluang
PROCEPT BIOROBOTICS CORPORATION (PRCT) INVESTOR ALERT - GlobeNewswire
Procept Biorobotics Corp (PRCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Procept BioRobotics faces class action lawsuit over inflated sales and undisclosed inventory issues. - Pluang
PRCT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against PROCEPT BioRobotics Corporation and Announces Opportunity for Investors with Substantial Losses to Lead the Procept Class Action Lawsuit - PR Newswire
INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Intuit Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Class action lawsuit alleges PROCEPT BioRobotics inflated revenue via aggressive discounting. - Pluang
Procept BioRobotics: Filling Robots Slower Than Placing Them (NASDAQ:PRCT) - Seeking Alpha
Procept Biorobotics Corp (PRCT) Cash Flow - TradingKey
PRCT|Procept Biorobotics Corp|Price:17.700|Chg%:+1.010 - TradingKey
PRCT|Procept Biorobotics Corp|Price:17.480| - TradingKey
Procept Biorobotics Corp (PRCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Procept Biorobotics Corp (PRCT) Institutional Confidence - TradingKey
PRCT Investors Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit with the Schall Law Firm - The Daily Tribune News
Procept Biorobotics Corp (PRCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PRCT|Procept Biorobotics Corp|Price:17.250|Chg%:+0.560 - TradingKey
Procept Biorobotics Corp. (PRCT) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Procept Biorobotics Corp. (PRCT) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Procept Biorobotics Corp (PRCT) Income Statement - TradingKey
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors Who Suffered Losses May Be Eligible to Participate in Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses - The AI Journal
PRCT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files - GlobeNewswire
Procept Biorobotics Corp (PRCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Procept Biorobotics stock hits 52-week low at $17.95 By Investing.com - Investing.com South Africa
Procept Biorobotics stock hits 52-week low at $17.95 - Investing.com
PROCEPT BioRobotics Corporation (PRCT): Investor Outlook on a Potential 52% Upside in the Healthcare Sector - DirectorsTalk Interviews
Analysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX), Protagonist Therapeutics (PTGX) and PROCEPT BioRobotics (PRCT) - The Globe and Mail
PROCEPT BioRobotics (PRCT) Gains On Coverage And Trial Progress, Is The Stock Still Cheap? - Sahm
Mobia Medical (MOBI) names ex-PROCEPT CEO Reza Zadno as director - Stock Titan
Procept Biorobotics Corp stock hits 52-week low at 19.2 USD - Investing.com Nigeria
PROCEPT BioRobotics to report Q2 2026 results on August 4 - scanx.trade
Procept Biorobotics Corp stock hits 52-week low at 19.2 USD By Investing.com - Investing.com South Africa
PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026 - The Manila Times
PROCEPT BioRobotics to Report Second Quarter 2026 Financial Results on August 4th, 2026 - Moomoo
PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20 - Stocktwits
Procept BioRobotics shares slide after Leerink downgrade cites rising competitive risks - MSN
Pooja Sharma Net Worth (2026) - GuruFocus
Truist Financial Sticks to Its Hold Rating for PROCEPT BioRobotics (PRCT) - The Globe and Mail
PROCEPT BioRobotics stock stays guided by procedure demand - AD HOC NEWS
Truist Downgrades PROCEPT BioRobotics to Hold From Buy, Lowers Price Target to $25 From $30 - marketscreener.com
PRCTProcept BioRobotics Corp Dividends - Finviz
Truist cuts Procept BioRobotics stock rating on reimbursement concerns By Investing.com - Investing.com Nigeria
Procept Biorobotics Corp (PRCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Procept Biorobotics Corp 주식 (PRCT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Waters Kevin | EVP, CFO |
Jun 08 '26 |
Sale |
28.48 |
357 |
10,167 |
151,201 |
| Templin Barry L | EVP, Chief Technology Officer |
Jun 08 '26 |
Sale |
28.48 |
358 |
10,195 |
68,953 |
자본화:
|
볼륨(24시간):